1-benzyloxycarbonyl-(2R)-tert-butyldimethylsilyloxymethyl-(3S)-hydroxypyrrolidine | 441718-01-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-benzyloxycarbonyl-(2R)-tert-butyldimethylsilyloxymethyl-(3S)-hydroxypyrrolidine
• 英文别名: benzyl (2R,3S)-2-[[tert-butyl(dimethyl)silyl]oxymethyl]-3-hydroxypyrrolidine-1-carboxylate
• CAS: 441718-01-0
• 化学式: C₁₉H₃₁NO₄Si
• 分子量: 365.545
• InChiKey: VBZHAKVGICITPW-SJORKVTESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.78
• 重原子数：
  25
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.63
• 拓扑面积：
  59
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-benzyloxycarbonyl-(2R)-tert-butyldimethylsilyloxymethyl-(3S)-hydroxypyrrolidine 在 四丁基氟化铵 、 sodium hydride 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 31.0h， 生成 1-benzyloxycarbonyl-(3S)-methoxy-(2R)-pyrrolidinemethanol
  参考文献：
  名称：

  A novel, potent, and orally active VLA-4 antagonist with good aqueous solubility: trans-4-[1-[[2-(5-Fluoro-2-methylphenylamino)-7-fluoro-6-benzoxazolyl]acetyl]-(5S)-[methoxy(methyl)amino]methyl-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid

  摘要：

  We have carried out the optimization of substituents at the C-3 or the C-5 position on the pyrrolidine ring of VLA-4 antagonist 3 with 2-(phenylamino)-7-fluorobenzoxazolyl moiety for the purpose of improving in vivo efficacy while maintaining good aqueous solubility. As a result, we successfully increased in vitro activity in the presence of 3% human serum albumin and achieved an exquisite lipophilic and hydrophilic balance of compounds suitable for oral administrative regimen. The modification resulted in the identification of zwitterionic compound 7n with (5S)-[methoxy(methyl) amino] methylpyrrolidine, which significantly alleviated bronchial hyper-responsiveness to acetylcholine chloride at 12.5 mg/kg, p.o. in a murine asthma model and showed favorable aqueous solubility (JP1, 89 mu g/mL; JP2, 462 mu g/mL). Furthermore, this compound showed good oral bioavailability (F = 54%) in monkeys. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.11.003
• 作为产物：
  描述：

  反-3-羟基-L-脯氨酸 在 锂硼氢 、 硫酸 、 碳酸氢钠 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 三乙胺 作用下， 以 四氢呋喃 、 乙醚 、 二氯甲烷 为溶剂， 生成 1-benzyloxycarbonyl-(2R)-tert-butyldimethylsilyloxymethyl-(3S)-hydroxypyrrolidine
  参考文献：
  名称：

  [EN] PYRROLOBENZODIAZEPINE COMPOUNDS
  [FR] COMPOSÉS PYRROLOBENZODIAZÉPINE

  摘要：

  该发明涉及式(I)的吡咯并[2,1-c][1,4]苯二氮杂环己烯（PBDs），特别是通过C1位置连接的PBD二聚体，以及通过C1位置连接到芳基的PBD单体，以及其药用可接受的盐，这些化合物可用作药物，特别是作为抗增殖剂。其中：虚线表示C1和C2或C2和C3之间的双键的可选存在；R2-R7是独立选择的取代基团；且：（i）R8和R9一起形成一个双键；（ii）R8为H且R9为OH；或者（iii）R8为H且R9为ORA，RA为C1-6烷基；其中R1具有以下结构式：-X-L-X'-D -X-L-X'-为一个连接基团，D具有结构式（II）或（III）；或者该化合物是一个二聚体，每个单体相同或不同，具有式（I），其中第一个单体的R1和第二个单体的R'1或R'6，或第一个单体的R6和第二个单体的R'1，共同形成一个具有结构式-X-L-X'-的桥连接单体的桥。

  公开号：

  WO2015166289A1

文献信息

• [EN] PYRROLOBENZODIAZEPINE COMPOUNDS<br/>[FR] COMPOSÉS PYRROLOBENZODIAZÉPINE
  申请人：FEMTOGENIX LTD

  公开号：WO2015166289A1

  公开（公告）日：2015-11-05

  The invention relates to pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) of formula (I) and in particular to PBD dimers linked through the C1 position, and PBD monomers linked through the C1 position to aromatic groups, and pharmaceutically acceptable salts thereof, which are useful as medicaments, in particular as anti-proliferative agents. (I) and salts or solvates thereof, wherein: the dotted lines indicates the optional presence of a double bond between C1 and C2 or C2 and C3; R2-R7 are independently selected substituent groups; and either: (i) R8 and R9 together form a double bond; (ii) R8 is H and R9 is OH; or (iii) R8 is H and R9 is ORA and RA is C1-6 alkyl; where R1 has the formula: -X-L-X'-D -X-L-X'- is a linker group and D has the formula (II) or (III): or where the compound is a dimer with each monomer being the same or different and being of formula (I) where the R1 of the first monomer and R'1 or R'6 of the second monomer, or R6 of the first monomer and R'1 of the second monomer, form together a bridge having the formula -X-L-X'- linking the monomers.

  该发明涉及式(I)的吡咯并[2,1-c][1,4]苯二氮杂环己烯（PBDs），特别是通过C1位置连接的PBD二聚体，以及通过C1位置连接到芳基的PBD单体，以及其药用可接受的盐，这些化合物可用作药物，特别是作为抗增殖剂。其中：虚线表示C1和C2或C2和C3之间的双键的可选存在；R2-R7是独立选择的取代基团；且：（i）R8和R9一起形成一个双键；（ii）R8为H且R9为OH；或者（iii）R8为H且R9为ORA，RA为C1-6烷基；其中R1具有以下结构式：-X-L-X'-D -X-L-X'-为一个连接基团，D具有结构式（II）或（III）；或者该化合物是一个二聚体，每个单体相同或不同，具有式（I），其中第一个单体的R1和第二个单体的R'1或R'6，或第一个单体的R6和第二个单体的R'1，共同形成一个具有结构式-X-L-X'-的桥连接单体的桥。
• A novel, potent, and orally active VLA-4 antagonist with good aqueous solubility: trans-4-[1-[[2-(5-Fluoro-2-methylphenylamino)-7-fluoro-6-benzoxazolyl]acetyl]-(5S)-[methoxy(methyl)amino]methyl-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid
  作者：Masaki Setoguchi、Shin Iimura、Yuuichi Sugimoto、Yoshiyuki Yoneda、Jun Chiba、Toshiyuki Watanabe、Fumihito Muro、Yutaka Iigo、Gensuke Takayama、Mika Yokoyama、Tomoe Taira、Misato Aonuma、Tohru Takashi、Atsushi Nakayama、Nobuo Machinaga

  DOI：10.1016/j.bmc.2012.11.003

  日期：2013.1

  We have carried out the optimization of substituents at the C-3 or the C-5 position on the pyrrolidine ring of VLA-4 antagonist 3 with 2-(phenylamino)-7-fluorobenzoxazolyl moiety for the purpose of improving in vivo efficacy while maintaining good aqueous solubility. As a result, we successfully increased in vitro activity in the presence of 3% human serum albumin and achieved an exquisite lipophilic and hydrophilic balance of compounds suitable for oral administrative regimen. The modification resulted in the identification of zwitterionic compound 7n with (5S)-[methoxy(methyl) amino] methylpyrrolidine, which significantly alleviated bronchial hyper-responsiveness to acetylcholine chloride at 12.5 mg/kg, p.o. in a murine asthma model and showed favorable aqueous solubility (JP1, 89 mu g/mL; JP2, 462 mu g/mL). Furthermore, this compound showed good oral bioavailability (F = 54%) in monkeys. (C) 2012 Elsevier Ltd. All rights reserved.